Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Taispeáin leaganacha eile (1)

Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2010

Míreanna comhchosúla

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
de réir: Mele, T, et al.
Foilsithe / Cruthaithe: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
de réir: Fox, S, et al.
Foilsithe / Cruthaithe: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
de réir: Fox, S, et al.
Foilsithe / Cruthaithe: (2011)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2009)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2007)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2008)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2006)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
de réir: Fox, S, et al.
Foilsithe / Cruthaithe: (2006)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
de réir: Generali, D, et al.
Foilsithe / Cruthaithe: (2011)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
de réir: Foroni, C, et al.
Foilsithe / Cruthaithe: (2009)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
de réir: Allevi, G, et al.
Foilsithe / Cruthaithe: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
de réir: Allevi, G, et al.
Foilsithe / Cruthaithe: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
de réir: Andreis, D, et al.
Foilsithe / Cruthaithe: (2016)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
de réir: Milani, M, et al.
Foilsithe / Cruthaithe: (2009)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
de réir: A Ianza, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Tamoxifen for Breast Cancer
de réir: A Karn, et al.
Foilsithe / Cruthaithe: (2010-03-01)

Nanoparticle Effect on Interaction of Epirubicin with DNA
de réir: Leyla Karadurmus, et al.
Foilsithe / Cruthaithe: (2017-11-01)

WITHDRAWN: Tamoxifen for early breast cancer.
de réir: Clarke, M
Foilsithe / Cruthaithe: (2008)

Vitamin C-driven epirubicin loading into liposomes
de réir: Lipka D, et al.
Foilsithe / Cruthaithe: (2013-09-01)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
de réir: Kerstin Wimmer, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
de réir: Andreas Venizelos, et al.
Foilsithe / Cruthaithe: (2022-08-01)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
de réir: Yuntao Wang MS, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Screening of oral tamoxifen ocular toxicity in patients with breast cancer
de réir: Ahmed Tharwat, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Modern breast cancer therapy: from tamoxifen to T-cell engineering
de réir: Yu. A. Shevchenko, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Tamoxifen in breast conservation therapy.
de réir: Lee, K, et al.
Foilsithe / Cruthaithe: (1995)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
de réir: Yuanyuan Shen, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Effect of Two Administration Methods of Endostar Combined with Epirubicin on Breast Cancer in Mice
de réir: WU Jiao, et al.
Foilsithe / Cruthaithe: (2018-07-01)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
de réir: Liu L, et al.
Foilsithe / Cruthaithe: (2017-06-01)

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
de réir: Erdim Refik, et al.
Foilsithe / Cruthaithe: (2009-09-01)

Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.
de réir: Giatromanolaki, A, et al.
Foilsithe / Cruthaithe: (2002)

Early and late tamoxifen resistance in breast cancer
de réir: Abu Rabi Z., et al.
Foilsithe / Cruthaithe: (2010-01-01)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
de réir: Seo Yun Moon, et al.
Foilsithe / Cruthaithe: (2021-08-01)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
de réir: Lundgren Steinar, et al.
Foilsithe / Cruthaithe: (2010-06-01)

Sox2 promotes tamoxifen resistance in breast cancer cells
de réir: Marco Piva, et al.
Foilsithe / Cruthaithe: (2013-10-01)

Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer
de réir: Hany N. Azzam, et al.
Foilsithe / Cruthaithe: (2022-09-01)